Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.